| Acquired by | Celgene |
| Price | $640M |
| Date | 12/09 |
| Terms | Cash and Stock |
| Website | gloucesterpharma.com |
| Category | BioTech |
| Phone | 617-583-1300 |
| Employees |
| Series D, 8/09 Novo Ventures Apple Tree Partners ProQuest Investments Prospect Venture Partners Rho Capital Partners | $29M |
Gloucester Pharmaceuticals is a biopharmaceutical company owned by Celgene that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester’s first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.
